Table 2.
Peptide | Structure | mMC1R | mMC3R | mMC4R | mMC5R | ||
---|---|---|---|---|---|---|---|
| |||||||
Agonist EC50 (μM) |
Antagonist pA2 |
Ki (nM) |
Antagonist pA2 |
Ki (nM) |
Agonist EC50 (μM) |
||
| |||||||
hAGRP (87–132)* | >100,000 | 8.9±0.2 | 1.3 | 9.4±1.0 | 0.40 | >100,000 | |
miniAGRP (87-120)* | >100,000 | 8.1±0.1 | 7.9 | 8.5±0.1 | 3.2 | >100,000 | |
hAGRP (109-118)* | 5.1±3.0 | >100,000 | 6.8±0.2 | 160 | >100,000 | ||
SHU9119* | Ac-Nle-c[Asp-His-DNal(2′)-Arg-Trp-Lys]-NH2 | 0.64±0.26 nM | 9.5 | 0.32 | 10.4 | 0.040 | 2.31±0.45nM |
1 | 6.1±1.8 | 6.1±0.3 | 790 | 6.5±0.2 | 320 | >100,000 | |
2 | 11.7±4.0 | 6.2±0.2 | 630 | 6.8±0.2 | 160 | >100,000 | |
3 | 7.3±3.1 | 6.2±0.2 | 630 | 7.2±0.1 | 63 | >100,000 | |
4 | c[Pro-Tyr-Ala-Arg-Phe-Phe-Asn-Ala-Phe-Ala-Tyr-DPro] | 17.6±10.1 | >100,000 | >100,000 | >100,000 | ||
5 | c[Pro-Tyr-Thr-Arg-Phe-Phe-Asn-Ala-Phe-Thr-Tyr-DPro] | 11.6±5.0 | 5.9±0.1 | 1,300 | 6.8±0.2 | 160 | >100,000 |
6 | c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] | 4.5±0.2 | 6.4±0.2 | 400 | 7.7±0.1 | 20 | >100,000 |
The indicated errors represent the standard error of the mean determined from at least three independent experiments >100,000 indicates that the compound was examined but lacked agonist activity at up to 100 μM concentrations. (*) The values indicated for hAGRP(87-132), miniAGRP, hAGRP(109-118) and SHU9119 have previously been reported.28,70